S&P Futures
3,810.00-6.75(-0.18%)Dow Futures
31,223.00-13.00(-0.04%)Nasdaq Futures
12,649.50-32.25(-0.25%)
Gracell Biotechnologies Inc. (GRCL)
Chart Events
Performance Outlook
| Previous Close | 24.10 |
| Open | 24.62 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1100 |
| Day's Range | 23.60 - 23.92 |
| 52 Week Range | 20.12 - 33.70 |
| Volume | 10,791 |
| Avg. Volume | 347,186 |
| Market Cap | 1.56B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Barrons.com
Tegna, Clear Channel Outdoor See Activist Action
Standard General reduced its position in television-station operator Tegna. Ares Management disclosed a large stake in billboards and advertising-signage company Clear Channel Outdoor.
- PR Newswire
Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL
Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the National Medical Products Administration (NMPA) in China has approved an investigational new drug (IND) application to study GC019F, a FasTCAR-enabled chimeric antigen receptor (CAR)-T therapy in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL).
- PR Newswire
Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products
Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted the Medical Products Manufacturing Certificate (MPMC) from the Jiangsu Medical Products Administration (JSMPA, Jiangsu is a province/state in China) for its CAR-T cell therapy products. The certification was granted on January 4, 2021, and indicates that Gracell's site in Suzhou Industrial Park (SIP) has fully met the compliance requirements for Good Manufacturing Practice (GMP) in relation to the production of CAR-T cell therapy for cancer treatment.
